Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : IC 800
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : US Army Medical Research Acquisition Activity
Deal Size : $1.0 million
Deal Type : Funding
Details : The award will be used for the development and preclinical studies of IC 800, a novel therapy for the topical treatment of ocular pain, utilizing the body’s endogenous pain controllers, the enkephalins.
Product Name : IC 800
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 28, 2021
Lead Product(s) : IC 800
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : US Army Medical Research Acquisition Activity
Deal Size : $1.0 million
Deal Type : Funding
Lead Product(s) : IC 265
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Ophthalmology Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The exclusive license is for ophthalmic indications in China and other countries of Southeast Asia. The agreement will accelerate the development of IC 265 and IC 270 in both China and the U.S.
Product Name : IC 265
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 28, 2020
Lead Product(s) : IC 265
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Ophthalmology Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Reset All
